Author: GT Medical Technologies

ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases

May 30, 2026
Prospective Multicenter Registry Study Reports High Local Tumor Control Following Resection with GammaTile® in Newly Diagnosed Brain Metastases

February 26, 2026

ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases